- Fasiglifam (TAK-875) | GPR40激动剂 | MCE
Fasiglifam 相关分类 Metabolic Disease GPCR G Protein Free Fatty Acid Receptor
- Fasiglifam: Uses, Interactions, Mechanism of Action | DrugBank Online
Fasiglifam has been used in trials studying the treatment of Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Diabetes Mellitus, Type 2
- Fasiglifam (Fasiglifam) - 药物靶点：GPR40 x STAT3_在研适应症：炎症_专利_临床_研发
Fasiglifam, a candidate targeting GPR40, showed efficacy in clinical trials for type 2 diabetes but exerted liver toxicity
- Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective . . .
TAK-875, a GPR40 agonist, was withdrawn from Phase III clinical trials due to drug-induced liver injury (DILI) Mechanistic studies were conducted to identify potential DILI hazards (covalent binding burden (CVB), hepatic transporter inhibition, mitochondrial toxicity, and liver toxicity in rats) as …
- 武田制药产品研发线因Fasiglifam失败而遭受重创 - 丁香园
在决定中止糖尿病候选药物Fasiglifam的研发之后，武田制药遭遇了一次重大研发挫折，这款药物原计划明年上市。
- Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist . . .
Fasiglifam (TAK-875) a G-protein coupled receptor 40 (GPR40) agonist, significantly improves hyperglycemia without hypoglycemia and weight gain, the major side effects of conventional anti-diabetics
- Fasiglifam-靶点: FFAR1_适应症-临床_专利_批准
Fasiglifam是由武田药品工业株式会社研发的一种小分子药物，是一种FFAR1激动剂。 目前该药物最高研发阶段为终止，用于治疗二型糖尿病、慢性肾功能不全、心脏和血管疾病和糖尿病。
- 武田宣布终止开发糖尿病药物Fasiglifam（TAK-875）
经过对所有临床试验数据的慎重考虑及与各专家小组的商榷，武田权衡利弊后认为，Fasiglifam（TAK-875）用于治疗病患所带来的益处不能远超其可能引发的风险。 为此，武田自愿决定终止Fasiglifam的开发活动。
|